GW Pharmaceuticals Overview
- Founded
-
1998
- Status
-
Acquired/Merged
- Employees
-
1,161
- Latest Deal Type
-
M&A
- Financing Rounds
-
12
GW Pharmaceuticals General Information
Description
GW Pharmaceuticals PLC is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The company's lead product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol used for the treatment of a number of rare childhood-onset epilepsy disorders. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. Geographically its presence can be seen across the region of UK, Europe, US, Canada, and others.
Contact Information
- Sovereign House
- Vision Park, Histon
- Cambridge CB24 9BZ
- England, United Kingdom
GW Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
GW Pharmaceuticals Comparisons
Industry
Financing
Details
000000
000000
GW Pharmaceuticals Competitors (8)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Zogenix | Formerly VC-backed | Emeryville, CA | 000 | 00000 | 000000&0 | 00000 |
| 0000000 0000000000 | Formerly VC-backed | Devon, PA | 00 | 00000 | 000000&0 | 00000 |
| 000 000000000000 | Formerly VC-backed | South Plainfield, NJ | 0000 | 00000 | 00000000000 | 00000 |
| 00000 000000000000 | Pending Transaction (M&A) | Plano, TX | 000 | 00.000 | 000000&0 | 00.000 |
| 000000 | Corporation | Menlo Park, CA | 00 | 000.00 | 000000&0 | 000.00 |
GW Pharmaceuticals Patents
GW Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202307065-D0 | Novel compounds and uses thereof | Pending | 12-May-2023 | ||
| GB-202211753-D0 | Complex botanical preparations | Pending | 11-Aug-2022 | ||
| GB-202211755-D0 | Complex botanical preparations | Pending | 11-Aug-2022 | ||
| GB-202208810-D0 | Crystaline forms of a synthetic cannabinoid | Pending | 15-Jun-2022 | 0000000000 | |
| GB-202206506-D0 | Crystaline forms of a cannabidiol-like cannabinoid | Pending | 04-May-2022 | C07C39/23 |
GW Pharmaceuticals Board Members (8)
| Name | Representing | Role | Since |
|---|---|---|---|
| 00000 00000 | Self | Board Member | 000 0000 |
| 00000 000000 | GW Pharmaceuticals | Board Member | 000 0000 |
GW Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
GW Pharmaceuticals Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|